Literature DB >> 33068222

A novel nomogram for predicting local recurrence-free survival after surgical resection for retroperitoneal liposarcoma from a Chinese tertiary cancer center.

Guoqiang Xue1, Zhen Wang1, Chengpeng Li1, Ang Lv1, Xiuyun Tian1, Jianhui Wu1, Hui Qiu1, Chunyi Hao2.   

Abstract

BACKGROUND: Local recurrence is the most difficult postoperative challenge and the leading cause of death in patients with retroperitoneal liposarcoma (RLPS). We aimed to establish a postoperative nomogram exclusively focused on RLPS for predicting local recurrence-free survival (LRFS).
METHODS: A cohort of 124 patients after surgical resection with curative intent in the Peking University Cancer Hospital Sarcoma Center were included in the study. Demographic, clinicopathologic, and treatment variables were analyzed using the Cox regression model. Significant clinically relevant variables in multivariable analysis were incorporated into the RLPS-specific nomogram. The discriminative ability and predictive accuracy of the nomogram were assessed by calculating the concordance index and drawing a calibration plot.
RESULTS: At a median follow-up of 26.5 (interquartile range 10.9-39.4) months, 71 patients had recurrent disease. The 3-year and 5-year LRFS rates were 35.6% (95% confidence interval, 27.0-46.9%) and 28.2% (95% CI 15.8-38.6%), respectively. Multivariate analysis identified the French Federation of Cancer Centers Sarcoma Group (FNCLCC) grade and completeness of resection as independent predictors of LRFS. Variables included in our nomogram were: presentation status, multifocality, completeness of resection, histologic subtypes, and FNCLCC grade. The concordance index of our nomogram was 0.732 (95% CI 0.667-0.797) and the calibration plot was excellent.
CONCLUSIONS: Our novel nomogram for patients with resected RLPS could improve recurrence risk stratification to explore molecular analysis associated with recurrence.

Entities:  

Keywords:  Local recurrence-free survival; Nomogram; Prognosis; Retroperitoneal liposarcoma

Year:  2020        PMID: 33068222     DOI: 10.1007/s10147-020-01796-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  32 in total

1.  Results of Resection for Recurrent or Residual Retroperitoneal Sarcoma After Failed Primary Treatment.

Authors:  Trevor D Hamilton; Amanda J Cannell; Minji Kim; Charles N Catton; Martin E Blackstein; Brendan C Dickson; Rebecca A Gladdy; Carol J Swallow
Journal:  Ann Surg Oncol       Date:  2016-08-23       Impact factor: 5.344

Review 2.  Liposarcoma: new entities and evolving concepts.

Authors:  A P Dei Tos
Journal:  Ann Diagn Pathol       Date:  2000-08       Impact factor: 2.090

3.  Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule.

Authors:  James O Park; Li-Xuan Qin; Francesco P Prete; Cristina Antonescu; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

4.  Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.

Authors:  Samuel Singer; Cristina R Antonescu; Elyn Riedel; Murray F Brennan
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

Review 5.  Multiply recurrent retroperitoneal liposarcoma.

Authors:  Sanjay P Bagaria; Emmanuel Gabriel; Gary N Mann
Journal:  J Surg Oncol       Date:  2017-12-19       Impact factor: 3.454

Review 6.  Retroperitoneal liposarcoma: a comprehensive review.

Authors:  Adarsh Vijay; Lakshmi Ram
Journal:  Am J Clin Oncol       Date:  2015-04       Impact factor: 2.339

7.  Long-term outcomes in treatment of retroperitoneal sarcomas: A 15 year single-institution evaluation of prognostic features.

Authors:  Eihab Abdelfatah; Angela A Guzzetta; Neeraja Nagarajan; Christopher L Wolfgang; Timothy M Pawlik; Michael A Choti; Richard Schulick; Elizabeth A Montgomery; Christian Meyer; Katherine Thornton; Joseph Herman; Stephanie Terezakis; Deborah Frassica; Nita Ahuja
Journal:  J Surg Oncol       Date:  2016-04-13       Impact factor: 3.454

8.  500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance.

Authors:  Amer H Zureikat; Joal D Beane; Mazen S Zenati; Amr I Al Abbas; Brian A Boone; A James Moser; David L Bartlett; Melissa E Hogg; Herbert J Zeh
Journal:  Ann Surg       Date:  2021-05-01       Impact factor: 13.787

Review 9.  Clinical and Molecular Spectrum of Liposarcoma.

Authors:  Alex Thomas John Lee; Khin Thway; Paul H Huang; Robin Lewis Jones
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

10.  Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group.

Authors:  Rick L M Haas; Sylvie Bonvalot; Rosalba Miceli; Dirk C Strauss; Carol J Swallow; Peter Hohenberger; Frits van Coevorden; Piotr Rutkowski; Dario Callegaro; Andrew J Hayes; Charles Honoré; Mark Fairweather; Rebecca Gladdy; Jens Jakob; Milena Szacht; Marco Fiore; Peter W Chung; Winan J van Houdt; Chandrajit P Raut; Alessandro Gronchi
Journal:  Cancer       Date:  2019-01-02       Impact factor: 6.860

View more
  3 in total

1.  Development and Validation of a Prognostic Model to Predict the Prognosis of Patients With Retroperitoneal Liposarcoma: A Large International Population-Based Cohort Study.

Authors:  Yiding Li; Guiling Wu; Yujie Zhang; Wanli Yang; Xiaoqian Wang; Lili Duan; Liaoran Niu; Junfeng Chen; Wei Zhou; Jinqiang Liu; Helun Zhong; Daiming Fan; Liu Hong
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

2.  Prognostic Factor Analysis and Nomogram Construction of Primary Retroperitoneal Liposarcoma: A Review of 10 Years of Treatment Experience in a Single Asian Cohort of 211 Cases.

Authors:  Aobo Zhuang; Aojia Zhuang; Qian Wu; Weiqi Lu; Hanxing Tong; Yong Zhang
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

3.  Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma.

Authors:  Aobo Zhuang; Qian Wu; Hanxing Tong; Yong Zhang; Weiqi Lu
Journal:  Cancer Manag Res       Date:  2021-08-24       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.